Drug Profile
Research programme: age-related macular degeneration therapeutics - BioInvent/Immusol
Latest Information Update: 22 Oct 2010
Price :
$50
*
At a glance
- Originator BioInvent International; Immusol
- Class Antibodies
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Age-related macular degeneration
Most Recent Events
- 22 Oct 2010 Discontinued - Preclinical for Age-related macular degeneration in Sweden (Parenteral)
- 22 Oct 2010 Discontinued - Preclinical for Age-related macular degeneration in USA (Parenteral)
- 17 May 2006 Preclinical trials in Age-related macular degeneration in Sweden (unspecified route)